606 related articles for article (PubMed ID: 27742498)
1. Role and mechanism of action of sclerostin in bone.
Delgado-Calle J; Sato AY; Bellido T
Bone; 2017 Mar; 96():29-37. PubMed ID: 27742498
[TBL] [Abstract][Full Text] [Related]
2. Sclerostin neutralization unleashes the osteoanabolic effects of Dkk1 inhibition.
Witcher PC; Miner SE; Horan DJ; Bullock WA; Lim KE; Kang KS; Adaniya AL; Ross RD; Loots GG; Robling AG
JCI Insight; 2018 Jun; 3(11):. PubMed ID: 29875318
[TBL] [Abstract][Full Text] [Related]
3. Resorption controls bone anabolism driven by parathyroid hormone (PTH) receptor signaling in osteocytes.
Rhee Y; Lee EY; Lezcano V; Ronda AC; Condon KW; Allen MR; Plotkin LI; Bellido T
J Biol Chem; 2013 Oct; 288(41):29809-20. PubMed ID: 23963454
[TBL] [Abstract][Full Text] [Related]
4. Targeted inhibition of sclerostin for post-menopausal osteoporosis therapy: A critical assessment of the mechanism of action.
Bhattacharyya S; Pal S; Chattopadhyay N
Eur J Pharmacol; 2018 May; 826():39-47. PubMed ID: 29476877
[TBL] [Abstract][Full Text] [Related]
5. Effects of intermittent parathyroid hormone (PTH) administration on SOST mRNA and protein in rat bone.
Silvestrini G; Ballanti P; Leopizzi M; Sebastiani M; Berni S; Di Vito M; Bonucci E
J Mol Histol; 2007 Aug; 38(4):261-9. PubMed ID: 17549589
[TBL] [Abstract][Full Text] [Related]
6. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis.
Bellido T; Ali AA; Gubrij I; Plotkin LI; Fu Q; O'Brien CA; Manolagas SC; Jilka RL
Endocrinology; 2005 Nov; 146(11):4577-83. PubMed ID: 16081646
[TBL] [Abstract][Full Text] [Related]
7. Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt/beta-catenin signaling.
Lin C; Jiang X; Dai Z; Guo X; Weng T; Wang J; Li Y; Feng G; Gao X; He L
J Bone Miner Res; 2009 Oct; 24(10):1651-61. PubMed ID: 19419300
[TBL] [Abstract][Full Text] [Related]
8. Does osteocytic SOST suppression mediate PTH bone anabolism?
Kramer I; Keller H; Leupin O; Kneissel M
Trends Endocrinol Metab; 2010 Apr; 21(4):237-44. PubMed ID: 20074973
[TBL] [Abstract][Full Text] [Related]
9. Successful induction of sclerostin in human-derived fibroblasts by 4 transcription factors and its regulation by parathyroid hormone, hypoxia, and prostaglandin E2.
Fujiwara M; Kubota T; Wang W; Ohata Y; Miura K; Kitaoka T; Okuzaki D; Namba N; Michigami T; Kitabatake Y; Ozono K
Bone; 2016 Apr; 85():91-8. PubMed ID: 26851122
[TBL] [Abstract][Full Text] [Related]
10. Role of Wnt signaling and sclerostin in bone and as therapeutic targets in skeletal disorders.
Marini F; Giusti F; Palmini G; Brandi ML
Osteoporos Int; 2023 Feb; 34(2):213-238. PubMed ID: 35982318
[TBL] [Abstract][Full Text] [Related]
11. Osteocyte-derived sclerostin inhibits bone formation: its role in bone morphogenetic protein and Wnt signaling.
ten Dijke P; Krause C; de Gorter DJ; Löwik CW; van Bezooijen RL
J Bone Joint Surg Am; 2008 Feb; 90 Suppl 1():31-5. PubMed ID: 18292354
[TBL] [Abstract][Full Text] [Related]
12. [Expression and regulation of the SOST gene].
Qin LJ; Ding DX; Cui LL; Huang QY
Yi Chuan; 2013 Aug; 35(8):939-47. PubMed ID: 23956082
[TBL] [Abstract][Full Text] [Related]
13. SOST is a target gene for PTH in bone.
Keller H; Kneissel M
Bone; 2005 Aug; 37(2):148-58. PubMed ID: 15946907
[TBL] [Abstract][Full Text] [Related]
14. The sclerostin story: from human genetics to the development of novel anabolic treatment for osteoporosis.
Yavropoulou MP; Xygonakis C; Lolou M; Karadimou F; Yovos JG
Hormones (Athens); 2014; 13(4):323-37. PubMed ID: 25555179
[TBL] [Abstract][Full Text] [Related]
15. The role of BMPs in bone anabolism and their potential targets SOST and DKK1.
Kamiya N
Curr Mol Pharmacol; 2012 Jun; 5(2):153-63. PubMed ID: 21787290
[TBL] [Abstract][Full Text] [Related]
16. Disparate bone anabolic cues activate bone formation by regulating the rapid lysosomal degradation of sclerostin protein.
Gould NR; Williams KM; Joca HC; Torre OM; Lyons JS; Leser JM; Srikanth MP; Hughes M; Khairallah RJ; Feldman RA; Ward CW; Stains JP
Elife; 2021 Mar; 10():. PubMed ID: 33779549
[TBL] [Abstract][Full Text] [Related]
17. Sclerostin and Bone Aging: A Mini-Review.
Hay E; Bouaziz W; Funck-Brentano T; Cohen-Solal M
Gerontology; 2016; 62(6):618-623. PubMed ID: 27177738
[TBL] [Abstract][Full Text] [Related]
18. Identification of the disease-causing gene in sclerosteosis--discovery of a novel bone anabolic target?
Balemans W; Van Hul W
J Musculoskelet Neuronal Interact; 2004 Jun; 4(2):139-42. PubMed ID: 15615113
[TBL] [Abstract][Full Text] [Related]
19. N-cadherin restrains PTH repressive effects on sclerostin/SOST by regulating LRP6-PTH1R interaction.
Yang H; Dong J; Xiong W; Fang Z; Guan H; Li F
Ann N Y Acad Sci; 2016 Dec; 1385(1):41-52. PubMed ID: 27723935
[TBL] [Abstract][Full Text] [Related]
20. Genetics of Sost/SOST in sclerosteosis and van Buchem disease animal models.
Sebastian A; Loots GG
Metabolism; 2018 Mar; 80():38-47. PubMed ID: 29080811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]